Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of Org 25969 for reversal of rocuronium-induced neuromuscular block in pediatric and adult subjects
2004-003819-23Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jan 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Sugammadex (5 arms), sponsored by Organon & Co. Primary endpoint: Time to recovery of T4/T1 ratio to 0.9. Started Jan 2005; status: completed.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on 2004-003819-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003819-23.